MX2009013581A - Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio. - Google Patents

Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.

Info

Publication number
MX2009013581A
MX2009013581A MX2009013581A MX2009013581A MX2009013581A MX 2009013581 A MX2009013581 A MX 2009013581A MX 2009013581 A MX2009013581 A MX 2009013581A MX 2009013581 A MX2009013581 A MX 2009013581A MX 2009013581 A MX2009013581 A MX 2009013581A
Authority
MX
Mexico
Prior art keywords
formula
provides
potassium channel
channel modulators
azacycloalkyl
Prior art date
Application number
MX2009013581A
Other languages
English (en)
Spanish (es)
Inventor
La Rosa Martha Alicia De
Jean-Michel Vernier
Samedy Ouk
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of MX2009013581A publication Critical patent/MX2009013581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2009013581A 2007-06-13 2008-06-13 Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio. MX2009013581A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93439607P 2007-06-13 2007-06-13
US12/138,251 US8367684B2 (en) 2007-06-13 2008-06-12 Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
PCT/US2008/066984 WO2008157404A2 (en) 2007-06-13 2008-06-13 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Publications (1)

Publication Number Publication Date
MX2009013581A true MX2009013581A (es) 2010-01-26

Family

ID=40137141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013581A MX2009013581A (es) 2007-06-13 2008-06-13 Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.

Country Status (18)

Country Link
US (1) US8367684B2 (https=)
EP (1) EP2170861B1 (https=)
JP (1) JP2010530002A (https=)
KR (1) KR20100018618A (https=)
CN (1) CN101868451A (https=)
AU (1) AU2008266009B2 (https=)
BR (1) BRPI0812564A2 (https=)
CA (1) CA2689208A1 (https=)
DK (1) DK2170861T3 (https=)
ES (1) ES2392774T3 (https=)
HR (1) HRP20120857T1 (https=)
MX (1) MX2009013581A (https=)
PL (1) PL2170861T3 (https=)
PT (1) PT2170861E (https=)
RU (1) RU2010100893A (https=)
SI (1) SI2170861T1 (https=)
TW (1) TW200914452A (https=)
WO (1) WO2008157404A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2421863A1 (en) 2009-04-21 2012-02-29 NeuroSearch AS Substituted naphthyridine derivatives and their medical use
CA2804165C (en) * 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
KR20150000900A (ko) 2012-04-10 2015-01-05 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 1-치환된 인다졸 유도체
CN108250128A (zh) * 2012-09-27 2018-07-06 江苏先声药业有限公司 作为钾通道调节剂的化合物
US10702057B2 (en) 2015-07-07 2020-07-07 Colgate-Palmolive Company Oral care implement and monofilament bristle for use with the same
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN118451079A (zh) * 2021-12-31 2024-08-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3369315D1 (en) 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (https=) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
FI971334A7 (fi) * 1994-08-03 1997-04-01 Asta Medica Ag Indoli-, indatsoli-, pyridopyrroli- ja pyridopyratsolijohdannaiset, jo illa on antiastmaattinen, antiallerginen, anti-inflammatorinen ja immu nomoduloiva vaikutus
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
EP2301562B1 (en) 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
IN188411B (https=) * 1997-03-27 2002-09-21 Yuhan Corp
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
EP1004316B1 (en) 1997-08-08 2005-11-02 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetic complications
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
JP2002542147A (ja) 1998-12-14 2002-12-10 セレジィ ファーマシューティカルス， インコーポレイテッド 肛門直腸障害の処置のための組成物および方法
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
EP1200073B1 (en) 1999-07-06 2007-01-10 Eli Lilly And Company SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
NZ516610A (en) 1999-08-04 2004-05-28 Icagen Inc Benzanilides as potassium channel openers
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6951863B2 (en) * 2001-02-07 2005-10-04 Ortho-Mcneil Pharmaceutical, Inc. Pyridoarylphenly oxazolidinone antibacterials, and related compositions and methods
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
EP1581510A4 (en) 2002-11-22 2006-08-30 Bristol Myers Squibb Co 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER
EP1585522B1 (en) 2002-12-23 2010-11-17 Icagen, Inc. Quinazolinones as potassium channel modulators
MXPA05006463A (es) 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
WO2004080950A1 (en) 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
BRPI0408437A (pt) 2003-03-21 2006-04-04 Lundbeck & Co As H derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
EP1631546A1 (en) 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
JP2006528231A (ja) 2003-05-27 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
US7276608B2 (en) * 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TW200530235A (en) * 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
KR20070030196A (ko) 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
CA2565154A1 (en) 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
CA2589001A1 (en) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1861394A1 (en) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
AU2006306542B2 (en) * 2005-10-21 2012-04-19 Merck Sharp & Dohme Corp. Potassium channel inhibitors
BRPI0716715B1 (pt) 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
CA2670966A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US9096518B2 (en) * 2009-06-22 2015-08-04 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof

Also Published As

Publication number Publication date
TW200914452A (en) 2009-04-01
US20080318979A1 (en) 2008-12-25
SI2170861T1 (sl) 2012-12-31
RU2010100893A (ru) 2011-07-20
AU2008266009B2 (en) 2013-06-06
US8367684B2 (en) 2013-02-05
AU2008266009A1 (en) 2008-12-24
BRPI0812564A2 (pt) 2015-02-10
HRP20120857T1 (hr) 2012-11-30
PL2170861T3 (pl) 2013-01-31
CA2689208A1 (en) 2008-12-24
ES2392774T3 (es) 2012-12-13
EP2170861B1 (en) 2012-08-29
JP2010530002A (ja) 2010-09-02
WO2008157404A2 (en) 2008-12-24
KR20100018618A (ko) 2010-02-17
DK2170861T3 (da) 2012-11-26
CN101868451A (zh) 2010-10-20
WO2008157404A3 (en) 2009-02-19
EP2170861A2 (en) 2010-04-07
PT2170861E (pt) 2012-09-06

Similar Documents

Publication Publication Date Title
MX2009013581A (es) Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
TW200716528A (en) Cyclopropanecarboxamide derivatives
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
TW200806299A (en) Treatment of pain
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
UA104844C2 (uk) Похідні 1,3-дигідроімідазол-2-тіону як інгібітори дофамін-бета-гідроксилази
EA200970705A1 (ru) Новые фармацевтические композиции
GB0701366D0 (en) Novel pharmaceutical compositions
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
TW200639159A (en) Treatment of pain
MXPA05010020A (es) Derivados de oxamida.
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
TW200420292A (en) Benzofuran derivative

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration